You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK):中期收入達到1.06億元 同比增加22.5%
格隆匯 08-27 19:37

格隆匯8月27日丨藥明巨諾-B(02126.HK)發佈公吿,截至2025年6月30日止六個月,按國際財務報吿準則計量,收入為人民幣1.063億元,同比增加22.5%。該收入來自(i)公司目前處於商業化的產品倍諾達®的銷售;及(ii)公司向Juno授予JW sLVV生產工藝及相關技術知識(以及專利)的非獨家許可。

毛利同比增加48.9%至人民幣6510萬元,主要是由於sLVV許可授權帶來的增量貢獻。產品銷售毛利率由截至2024年6月30日止六個月的50.4%增至截至2025年6月30日止六個月的51.1%。公司持續致力於提升生產運營效率、探索改善流程的新技術,並實施我們的成本削減計劃。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account